Sodium-Glucose Cotransporter 2 Inhibitors Reduce Contrast-Induced Nephropathy in Patients with Heart Failure

Strategic Insights -

Researchers from the University for Health Sciences in Adana, Turkiye, have published a study investigating the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the development of contrast-induced nephropathy (CIN) in patients with heart failure with reduced ejection fraction (HFrEF) without diabetes mellitus (DM) undergoing elective coronary angiography (CAG) and percutaneous coronary intervention (PCI). The study, which included 390 patients, found that SGLT2i treatment decreased the incidence of CIN from 19.5% to 0%.

Key Takeaways:

  • The researchers included 390 patients in their study, with 242 men and 148 women, and a mean age of 63.7 years.
  • The patients were divided into two groups: those with and without CIN, and all parameters were compared to identify the determining factors for CIN.
  • CIN occurred in 76 (19.5%) of the 390 patients, and age was a significant predictor of CIN.
  • The study concluded that SGLT2i treatment did not entirely eliminate the risk of CIN but significantly reduced it, from 19.5% to 0%.
  • The researchers emphasized the need for multicenter prospective randomized controlled trials to support their findings.

The study was peer-reviewed and published in the Bratislava Medical Journal-bratislavske Lekarske Listy.

Statistics:

  • 390 patients were included in the study.
  • 76 (19.5%) of the patients developed CIN.
  • Age was a significant predictor of CIN (p = 0.001).
  • SGLT2i treatment reduced the incidence of CIN from 19.5% to 0%.
  • The study was conducted retrospectively after exclusion of certain criteria.

Sources:

  • Bratislava Medical Journal-bratislavske Lekarske Listy, 2025
  • University for Health Sciences, Adana Hlth Practice & Res Ctr, Dept. of Cardiology, Dr Mithat Ozsan Bulvari KislaMah 4522 Sok 1 Yuregi, Adana, Turkiye.
  • Aepress Sro, Bajzova 7, Bratislava, 821 08, Slovakia